Home Systems biology Codex DNA demonstrates a simple, scalable, cell-free approach for the rapid design of mRNA vaccines… | News

Codex DNA demonstrates a simple, scalable, cell-free approach for the rapid design of mRNA vaccines… | News

0

SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its keynote presentation for the World Vaccine Congress Washington 2022, held in Washington, DC. from April 18 to 21, 2022. The company will showcase its automated benchtop workstation – the BioXp™ System and its automated solutions to accelerate vaccine discovery workflows at booth #202.

The need for rapid vaccine development in response to emerging pathogens has become increasingly evident during the COVID-19 pandemic. However, traditional methods of vaccine discovery, development and production can be complicated for manufacturers, regulators and public health officials, especially for endemic viruses that require adjustments to counter ongoing antigenic variation. Codex DNA’s automated solution currently supports rapid DNA and mRNA synthesis from a digital sequence in a single automated run. The BioXp 3250 System enables customers to synthesize high quality DNA and biologically active mRNA in 24 hours, reducing turnaround time from weeks to days, increasing throughput and scale, improving quality and giving researchers complete control of the workflow. Codex DNA also expects its proprietary Short Oligonucleotide Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) approach to further enable on-demand synthesis of DNA, mRNA and proteins and shorten the timeline for discovery and development of vaccines, mRNA-based diagnostics and therapies, and personalized medicines.

Codex DNA and RNA have been work together to optimize the development and validation of future Codex DNA mRNA synthesis kits. In this effort, the two companies will also address the integration of RNAimmune’s proprietary mRNA delivery solutions into Codex DNA’s automated workflows to further streamline the vaccine discovery process.

“We are excited to work with Codex DNA to accelerate breakthroughs using mRNA platforms. Together, we can incorporate our proprietary carrier molecules into Codex DNA mRNA synthesis kits to enhance the automated production of truly transfection-ready mRNAs with enhanced uptake and expression,” said Dong Shen, Ph.D. , CEO of RNAimmune. RNAimmune will present the design and development of its novel Pan-Ras mRNA vaccine for the treatment of cancer at the conference and will also highlight the use of the BioXp™ system to accelerate their discovery workflows.

FEATURED CLIENT PRESENTATION: Targeting KRAS Mutations in Cancer: New mRNA Vaccine on the Horizon Track: Cancer and Immunotherapy Presenter: Dong Shen, MD, PhD​, President and CEO, RNAimmune​ Date/Time: Wednesday, April 20, 3:40 p.m. Location: M4, Liberty Salon IK

“Together with RNAimmune, we are empowering our customers to design, develop and produce safe, high-quality vaccines faster than ever before,” said Todd R. Nelson, PhD, CEO of Codex DNA. “I am delighted that conference attendees will hear directly from Dr. Shen about the impressive work being done in mRNA vaccines. Our sustainable, scalable, and cost-effective approach has the potential to completely transform how the world responds to emerging virus threats in the future.

Codex DNA currently offers a catalog of synthetic genomes, including SARS-CoV-2, for research purposes for monoclonal antibody treatments, small molecule therapies, diagnostic tests and new vaccines against specific variants. For more information, please visit the following link. About Codex DNA Codex DNA gives scientists the ability to create new synthetic biology-based solutions to many of humanity’s greatest challenges. As the inventor of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA enables fast, accurate and reproducible writing of DNA and mRNA for many downstream markets. The award-winning BioXp™ system consolidates, automates and optimizes the entire synthesis, cloning and amplification workflow. As a result, it offers virtually error-free large-scale DNA and RNA synthesis in days and hours instead of weeks or months. Scientists around the world are using this technology in their own labs to accelerate the design-build-test paradigm of new, high-value products for precision medicine, biologic drug discovery, vaccine and therapeutics development, genome and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.

Codex DNA, the Codex DNA logo, Gibson Assembly and BioXp are trademarks of Codex DNA Inc.

Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding Codex DNA’s progress toward achieving corporate goals and future release of products and services. These statements are based on current assumptions that involve risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties, many of which are beyond Codex DNA’s control, include those risks described in Codex DNA’s public documents, in particular the section titled Risk Factors and elsewhere in its annual report on Form 10-K, which is expected to be filed with the Securities and Securities and Exchange Commission on March 23, 2022. These forward-looking statements speak only as of the date hereof and should not be relied upon unduly. Codex DNA disclaims any obligation to update these forward-looking statements.

Media Contact Richard D. Lepke Director, Investor Relations ir@codexdna.com

Copyright 2022 GlobeNewswire, Inc.